These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25814011)

  • 1. [Hip Fracture--Epidemiology, Management and Liaison Service. Medicines that prevent hip fracture].
    Uchiyama S
    Clin Calcium; 2015 Apr; 25(4):505-9. PubMed ID: 25814011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of senile osteoporosis and hip fractures.
    Duque G; Demontiero O; Troen BR
    Minerva Med; 2009 Feb; 100(1):79-94. PubMed ID: 19277006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmaceutical treatment for patients with hip fracture].
    Hagino H
    Clin Calcium; 2010 Sep; 20(9):1394-400. PubMed ID: 20808048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy.
    Ramchand SK; Seeman E
    Handb Exp Pharmacol; 2020; 262():423-450. PubMed ID: 32232792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hip Fracture--Epidemiology, Management and Liaison Service. Prevention of the secondary hip fractures utilizing the regional post-referral treatment plan].
    Matsushita M
    Clin Calcium; 2015 Apr; 25(4):545-50. PubMed ID: 25814015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
    Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
    Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
    Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
    Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of Clinical Fracture Risk Reduction of Antiosteoporosis Drugs: Direct and Indirect Comparisons and Meta-Regressions.
    Albert SG; Wood E
    Endocr Pract; 2021 Nov; 27(11):1082-1092. PubMed ID: 34252583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is cortical bone hip? What determines cortical bone properties?
    Epstein S
    Bone; 2007 Jul; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
    Tanaka I; Oshima H
    Nihon Rinsho; 2009 May; 67(5):915-20. PubMed ID: 19432109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoporosis liaison service].
    Suzuki A
    Nihon Rinsho; 2015 Oct; 73(10):1765-9. PubMed ID: 26529944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of teriparatide in sequential and combination therapy of osteoporosis.
    Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
    Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures.
    Morin S; Rahme E; Behlouli H; Tenenhouse A; Goltzman D; Pilote L
    Osteoporos Int; 2007 Dec; 18(12):1625-32. PubMed ID: 17634854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.